NCT06590493

Doxecitine and Doxribtimine-Expanded Access

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: UCB BIOSCIENCES, Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

This Expanded Access Record for doxecitine and doxribtimine includes the following managed access programs and status: TK0113: Available TK0115: Available

Detailed description

TK0113: Data Collection for Patients in the Company Supported Expanded Access Program TK0115: TREATMENT PROTOCOL FOR DOXECITINE AND DOXRIBTIMINE - Company-sponsored Intermediate-size Cohort Expanded Access Program for Doxecitine and Doxribtimine for Patients with Thymidine Kinase 2 Deficiency (TK2d) with an Age of Symptom Onset ≤ 12 Years

Conditions

• Thymine Kinase 2 Deficiency

Interventions

Type	Name	Description
DRUG	doxecitine and doxribtimine	TK0113 and TK0115: Doxecitine and doxribtimine is dosed daily and will be administered orally or via feeding tube. The patient may continue to receive doxecitine and doxribtimine treatment within the EAP as long as the benefit / risk balance remains positive in the opinion of the treating physician or access to commercially available doxecitine and doxribtimine, when it becomes available.

Timeline

• First posted: 2024-09-19
• Last updated: 2025-09-12